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DOI 10.1016/j.chembiol.2011.09.002In the earliest stages of angiogenesis,
vascular endothelial cells respond to
chemical signals and start to proliferate.
Before long, the cells send the integrin
avb3 and the platelet endothelial cell
adhesion molecule CD31/PECAM onto
their outer membranes like tiny flags.
Even though the endothelial cells have
not become polarized (oriented in a cer-
tain direction), the avb3 molecules are ex-
pressed within what will eventually be-
come the lumen of the vessel and the
outside of the vessel wall. Researchers
aiming to trace the origins of angiogenesis
for heart disease or cancer start in the
same place because each of these dis-
eases depends on the same blood vessel
formation process. Plaques and tumors
need a new blood supply to grow andResearchers aiming to trace the origins of angiogenesis for heart
disease or cancer start in the same place.survive. Detecting and even quantifying
the earliest expression of the cascade
of molecules during angiogenesis re-
quires probes or contrast agents specific
enough to detect surface molecules that
signal vessel formation.
Suchdetection requires probes that can
home in on these molecules and imaging
methodology sensitive enough to locate
the probes, allowing researchers to watch
changes in vessel formation over time
and illuminate the relationship between
angiogenesis and cancer and the level of
malignancy and metastasis. Those same
probes that can glomonto a surfacemole-
cule in the earliest stages of angiogenesis
can in turn deliver doses of chemotherapy
that could halt angiogenesis and block
a tumor’s blood and thus its energy sup-
ply. Because these probes play a dual
role as therapeutics and diagnostics,
they have been dubbed ‘‘theranostics.’’
Thanks to a flurry of research on a
variety of probes and imaging methods,
researchers today have probes in the
preclinical stage than can indeed lockonto molecules expressed during angio-
genesis and detect the probes down to
a spatial sensitivity of around 30–50 mm.
A variety of imaging modalities is
necessary because each technique has
its strengths and weaknesses, says Mario
Bourdon, Ph.D. founder and president
of BioLaurus Inc., a contract research
laboratory in San Diego, California, that
specializes in molecular imaging. An
assortment of probes in the preclinical
stage is being tested via many different
imaging technologies.
Start with the Heart
At Kereos Inc., a St. Louis, Missouri,
biotech company, researchers are devel-
oping and testing a product based on per-
fluorocarbon nanoparticles that recognizethe activated form of avb3 integrin on
budding endothelial cells.
The Kereos researchers modified a
nanoparticle that was originally tried as a
blood substitute. The nanoparticle could
circulate in the bloodstream and is bio-
logically inert but didn’t deliver oxygen
well to tissues. Although the nanoparticle
didn’t work as a blood substitute, Kereos
scientists modified the blood substitute
for magnetic resonance imaging, or MRI,
by replacing the hydrogen atoms with
fluorine.
‘‘We’re able to image both the proton
images that normal MRIs would see
and the fluorine images simultaneously
because there’s no background fluorine
in the body,’’ says Gregory Lanza, M.D.,
Ph.D., Kereos cofounder and professor
of medicine at Washington University
School ofMedicine inSt. Louis. The result-
ing image shows ‘‘hot spots’’ in the
vessels where the fluorine nanoparticles
are deposited.
The nanoparticles are currently in a
Phase 1 clinical trial aimed at looking atChemistry & Biology 18, September 23, 2011 ªthe relationship to carotid artery disease,
a condition in which fatty plaques build
up inside the carotid artery and raise the
risk of stroke. Researchers are looking
both for safety and for the ability to see
signals from carotids due to homing of
the ligand. Lanza says he and colleagues
hope that with angiogenesis imaging
they can identify the people who have
had a plaque hemorrhage and who
would most likely go on to have stroke
as opposed to those who wouldn’t;
right now, about 50% of those patients
can’t be identified well enough. The
current study, done in collaboration
with Phillips Healthcare, encompasses
patients who could have significant
carotid disease.
‘‘The beauty of angiogenesis is that is
shows exactly what’s going on in the
wall directly. If you give a drug that is
supposed to improve the complication
of atherosclerosis from diabetes rather
than looking at glucose and trying to
guess what happened in nonspecific in-
flammatory markers, you can use imaging
before and after to follow whether athero-
sclerosis or cancer is progressing, for
example, by determining whether angio-
genesis is getting greater or is subsiding,’’
says Lanza.
Once the safety of the nanoparticles is
well established, Lanza says the team
will expand to a cancer angiogenesis
and other applications.
Chicks and Eggs
Researchers at Innovascreen, Inc., in
Halifax, Nova Scotia, have ‘‘gone to the
birds’’ by fine-tuning an avian model
system that has been around for a long
time. For thousands of years, people
cracked open eggs to learn how living
systems are put together; Innovascreen
researchers are doing much the same
by studying the chicken chorioallantoic
membrane (CAM). This membrane sup-
plies the developing chick with oxygen
via gas exchange across the eggshell.
Because theCAMhasmanybloodvessels
and sits against the eggshell, it is a great2011 Elsevier Ltd All rights reserved 1065
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a self-sustained living organism that
allows researchers to study blood vessel
formation, says Andries Zijlstra, Ph.D.,
Chief Scientific Officer, Innovascreen.
By growing the CAM as a free-floating
organ in a culture dish, researchers have
a surface area of about 10 cm2 available
for bioassays. This amount of surface
area comes in handy during the screening
steps of Innovascreen’s assay. First, the
team transplants human tumors into
the CAM. By placing the culture dish on
the stage of a microscope hooked up for
intravital microscopy, researchers can
watch cellular movement and blood
vessel formation in real time. The CAM
model also allows the team to deliver
antitumor drugs via nanoparticles. John
Lewis, Ph.D., and the company’s chief
executive officer, developed an assay to
assess how deep the nanoparticles
penetrate into the tumor. ‘‘This is a robust
in vivo system that we’ve transformed
into a higher throughput model. Angio-
genesis isn’t static, it’s a dynamic pro-
cess, andwe can capture those dynamics
and simultaneously watch what a drug is
doing,’’ says Lewis.
Such an assay allows Innovascreen’s
team access to high-resolution imaging
at the microscopic level. Not only does
the CAM model support the growth of
human tumor cells, it’s less expensive
than using mice and surgery and anes-
thesia are unnecessary, says Lewis, and
the team can monitor the assays for up
to three days and then quantify the
results.
Tiny Bubbles
An emerging imaging technology being
used for angiogenesis is gas-encapsu-
lated microspheres that work as contrast
agents with ultrasound technology. Sono-
grams (or ultrasounds) work by shooting
sound waves into the body toward
a tumor, or a baby, or a beating heart.
The resulting image is captured as the
ultrasound machines detect the sound1066 Chemistry & Biology 18, September 23,waves as they bounce back. Traditional
ultrasound is not sensitive enough to
detect molecular events such as angio-
genesis, which happen on a very small
scale. Gas microbubbles boost this echo
by providing a contrast that is many times
brighter than anything else in the body,
explains Joshua (Jack) Rychak, Ph.D.,
and vice president for research of Targe-
son, a San Diego-based biotechnology
company.
Ligands specially attached to themicro-
bubbles work as contrast agents by tar-
geting angiogenic endothelium in tumors
and can thus be used as both molecular
imaging probes and a way to deliver
drugs. The data that emerge from these
studies is in real time and on a molecular
scale. Another advantage of this tech-
nique is that ultrasound machines are
portable and low cost compared to MRIs
or CT scans, says Rychak.
Targeson has developed two angiogen-
esis-targeted agents. One agent seeks
out integrins and the other, the com-
pany’s lead technology, targets vas-
cular endothelial growth factor receptor
(VEGFR2). Thus far, both targets have
been validated in mice and are commer-
cially available for research use.
Here’s how the microbubbles work:
Rychak injects a dispersion containing
the bubbles into the tail vein of a mouse.
The target is not actually the tumor.
Microbubbles are coated with a ligand
that binds to receptors on the newly
forming blood vessels, which is a hallmark
of a growing tumor, and provides a way
to differentiate the tumor from healthy
surrounding tissue. The team coated
microbubbles with an integrin-binding
ligand (an RGD pentapeptide) and found
that mouse tumors took up the bubbles
at a high, specific rate (Anderson et al.,
2011). ‘‘This was definitely a happy sur-
prise for us,’’ Rychak says, still amazed
with the results because RGD is a
common motif in the body, and he
cautions that the high binding could just
be happening in mice.2011 ª2011 Elsevier Ltd All rights reservedRychak’s team has recently completed
a study in companion dogs designed to
detect spontaneous prostate cancer.
‘‘We’ve already confirmed that when we
implant a tumor in a mouse or rat, we
can image it with our agents,’’ says
Rychak. ‘‘It’s easy when you already
know where the tumor is. The real chal-
lenge for us now is proving that we can
find a spontaneously occurring cancer.’’
The canine study looked at naturally
developing prostate cancer and evalu-
ated whether the agents can differentiate
prostate cancer from benign disease.
Although the data are still being prepared
for publication, Rychak says his team
was able to successfully detect naturally
occurring prostate cancer at relatively
early stages of development in dogs.
For now, researchers are using the
microbubbles for both basic science
studies and in the drug discovery
process. Many questions still need to be
answered on the kinetics and biome-
chanics of adhesion of the microbubbles
to the receptors. Because Targeson is
putting their agents out into the market
to make the technology available to
other researchers, ‘‘a fairly unique com-
mercial strategy,’’ says Rychak, that may
help answer some of these questions
and explain the progression of the
technology.
‘‘One company and one lab won’t be
able to answer all of these questions.
So if we can get the microbubble out
into the field and get others using it in
a meaningful way, then we’re contributing
to the overall field of knowledge,’’ says
Rychak.
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